(12) **Translation of European patent specification**

(11) **NO/EP 2970390 B1**

NORWAY

(19) NO

(51) Int Cl.

C07K 7/56 (2006.01)
A61K 38/12 (2006.01)
C07K 7/08 (2006.01)
G01N 33/68 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.02.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.11.06
(86)	European Application Nr.	14727649.7
(86)	European Filing Date	2014.03.13
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2013.03.15, US, 201361794589 P 2013.12.19, US, 201361918184 P 2014.03.10, US, 201414201977
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
(72)	Inventor	MILLER, Michael Matthew, c/o Bristol-Myers Squibb Company Route 206 and Province Line Road, Princeton, New Jersey 08543, USA MAPELLI, Claudio, c/o Bristol-Myers Squibb Company Route 206 and Province Line Road, Princeton, New Jersey 08543, USA ALLEN, Martin Patrick, c/o Bristol-Myers Squibb Company Route 206 and Province Line Road, Princeton, New Jersey 08543, USA BOWSHER, Michael S., c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA BOY, Kenneth M., c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA GILLIS, Eric P., c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA LANGLEY, David R., c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA MULL, Eric, c/o Bristol-Myers Squibb Company5 Research Parkway, Wallingford, Connecticut 06492, USA POIRIER, Maude A., c/o Bristol-Myers Squibb Company Route 206 and Province Line Road, Princeton, New Jersey 08543, USA SANGHVI, Nishith, 3 Kershaw Court, Bridgewater, New Jersey 08807, USA SUN, Li-Qiang, c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA

TENNEY, Daniel J., c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA
YEUNG, Kap-Sun, c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA
ZHU, Juliang, 22 Windsor Road East, North Haven, CT 06473, USA
REID, Patrick C., 1-17-10 Eifukucho Suginami-Ku, Tokyo 168-0064, Japan
SCOLA, Paul Michael, c/o Bristol-Myers Squibb Company 5 Research Parkway, Wallingford, Connecticut 06492, USA

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

---

(54) Title **MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS**

(56) References Cited:
WO-A1-2012/074130
WO-A1-00/26353
WO-A1-2012/033154
WO-A2-2009/114335
YUUKI HAYASHI ET AL: "In Vitro Selection of Anti-Akt2 Thioether-Macrocyclic Peptides Leading to Isoform-Selective Inhibitors", ACS CHEMICAL BIOLOGY, vol. 7, no. 3, 16 March 2012 (2012-03-16), pages 607-613, XP055133026, ISSN: 1554-8929, DOI: 10.1021/cb200388k
JIABEI HE ET AL: "Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer", SCIENTIFIC REPORTS, vol. 5, no. 1, 17 August 2015 (2015-08-17) , page 13110, XP055355997, DOI: 10.1038/srep13110
DONGSHENG HUANG: "Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells", MOLECULAR MEDICINE REPORTS, 27 June 2012 (2012-06-27), XP055133284, ISSN: 1791-2997, DOI: 10.3892/mmr.2012.970
YUSUKE YAMAGISHI ET AL: "Natural Product-Like Macrocyclic-Methyl-Peptide Inhibitors against a Ubiquitin Ligase Uncovered from a Ribosome-Expressed De Novo Library", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 18, no. 12, 20 September 2011 (2011-09-20), pages 1562-1570, XP028348893, ISSN: 1074-5521, DOI: 10.1016/J.CHEMBIOL.2011.09.013 [retrieved on 2011-10-11]
JUMPEI MORIMOTO ET AL: "Discovery of Macrocyclic Peptides Armed with a Mechanism-Based Warhead: Isoform-Selective Inhibition of Human Deacetylase SIRT2", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 51, no. 14, 28 February 2012 (2012-02-28), pages 3423-3427, XP55133046, ISSN: 1433-7851, DOI: 10.1002/anie.201108118

Patentkrav

1. Forbindelse valgt fra: og


;


;


;


;


;

5


;


;


;


;


;


;


;


;


;


;



;



;



;


;


;


;


;


;


;


;


;


;



;



;



;



;



;



;


;


;


;


;


;


;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;


;


;


;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;


;


;


;



;



;

5



;



;



;



;



;

5



;



;



;


;


;


;


;


;


;


;


;


;



;



;



;


;


;


;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;


;


;


;


;


;


;



;



;



;



;



;



;



;



;



;



;



;



5 :



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;


;


;


;



;



;



;


;


;


;



;



og



;

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelsene eller farmasøytisk akseptabelt salt derav ifølge krav 1 for anvendelse for å styrke, stimulere og/eller øke immunresponsen hos et individ med behov derav.

3. Forbindelsene eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 2 med et ytterligere middel før, etter eller samtidig med det makrosykliske peptidet eller peptider beskrevet heri.

4. Forbindelsene eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 3, hvori det ytterligere midlet er et antimikrobielt middel, et antivirusmiddel, et cytotoksisk middel og/eller en immunresponsmodifikator.

5. Forbindelsene eller farmasøytisk akseptabelt salt derav ifølge krav 1 for anvendelse for å inhibere vekst, spredning eller metastase av kreftceller hos et individ med behov derav.

6. Forbindelsene eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 5, hvori kreften velges fra melanom, nyrecellekarsinom, skvamøs ikke-småcellet lungekreft (NSCLC), ikke-skvamøs NSCLC, kolorektal kreft, kastreringsresistent prostatakreft, eggstokkreft, magekreft, hepatocellulært karsinom, bukspyttkjertelkarsinom, skvamøst cellekarsinom i hodet og nakken, karsinomer i spiserøret, mage-tarmkanalen og brystet, og en hematologisk malignitet.

7. Forbindelsene eller farmasøytisk akseptabelt salt derav ifølge krav 1 for anvendelse ved behandling av en smittsom sykdom hos et individ med behov derav.

8. Forbindelsene eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 7, hvori den smittsomme sykdommen er forårsaket av et virus.

9. Forbindelsene eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 8, hvori viruset er valgt fra HIV, hepatitt A, hepatitt B, hepatitt C, herpesvirus og influensa.

10. Forbindelsene eller farmasøytisk akseptabelt salt derav ifølge krav 1 for anvendelse ved behandling av septisk sjokk hos et individ med behov derav.

11. Forbindelsene eller farmasøytisk akseptabelt salt derav ifølge krav 1 for anvendelse i blokkering av interaksjonen mellom PD-L1 og PD-1 og/eller CD80 hos et individ.